Difference between revisions of "Gemcitabine (Gemzar)"
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Bladder cancer]] | ||
| + | *[[Bone cancer]] | ||
| + | *[[Breast cancer]] | ||
| + | *[[Cervical cancer]] | ||
| + | *[[Esophageal cancer]] | ||
| + | *[[Hepatobiliary cancer]] | ||
| + | *[[Hodgkin lymphoma]] | ||
| + | *[[Mesothelioma]] | ||
| + | *[[Non-small cell lung cancer]] | ||
| + | *[[Ovarian cancer]] | ||
| + | *[[Pancreatic cancer]] | ||
| + | *[[Renal cancer]] | ||
| + | *[[Sarcoma]] | ||
| + | *[[Small cell lung cancer]] | ||
| + | *[[T-cell lymphoma]] | ||
| + | *[[Testicular cancer]] | ||
| + | *[[Unknown primary]] | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 02:25, 21 June 2013
General information
Class/mechanism: Pyrimidine analog; metabolized within cells to the active nucleoside forms: diphosphate (dFdCDP) and triphosphate (dFdCTP). Gemcitabine diphosphate inhibits ribonucleotide reductase, which catalyzes reactions that produce deoxynucleoside triphosphates for DNA synthesis. This inhibition of deoxynucleoside triphosphates helps gemcitabine triphosphate to compete with deoxycytidine triphosphate (dCTP) to be incorporated into DNA. DNA synthesis is halted, since only one additional nucleotide can be added to a DNA strand after gemcitabine is incorporated.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Bladder cancer
- Bone cancer
- Breast cancer
- Cervical cancer
- Esophageal cancer
- Hepatobiliary cancer
- Hodgkin lymphoma
- Mesothelioma
- Non-small cell lung cancer
- Ovarian cancer
- Pancreatic cancer
- Renal cancer
- Sarcoma
- Small cell lung cancer
- T-cell lymphoma
- Testicular cancer
- Unknown primary
Patient drug information
- Gemcitabine (Gemzar) patient drug information (Chemocare)[3]
- Gemcitabine (Gemzar) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 5/15/1996: Initial FDA approval